favipiravir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 21 Diseases   35 Trials   35 Trials   2204 News 
49 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
favipiravir / Generic mfg.
ChiCTR1800015894: Clinical efficacy of therapy with T-705 in patients with severe fever with thrombocytopenia syndrome

Recruiting
4
160
 
Symptomatic treatment + T-705 treatment ; Symptomatic treatment + glucose injection
Beijing Institute of Microbiology and Epidemiology; People 's Liberation Army154 Hospital, National Natural Science Foundation of China (No. 81473023)
severe fever with thrombocytopenia syndrome
 
 
Favipiravir for SARS-Cov-2, ChiCTR2000033491: Oral Favipiravir for Patients with Delayed SARS-Cov-2 viral RNA Clearance

Completed
4
9
 
oral Favipiravir
Wuhan Huoshenshan Hosptial; Huoshenshan Hospital, Huoshenshan Hospita
Novel Coronavirus Pneumonia (COVID-19); viral infection
 
 
ChiCTR2000030894: Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial

Recruiting
4
150
 
Favipiravir Combined With Tocilizumab ;Favipiravir ;Tocilizumab
Peking University First Hospital; Peking University First Hospital, self-financed
Novel Coronavirus Pneumonia (COVID-19)
 
 
2020-001435-27: Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safetyof several experimental treatments to reduce the risk of hospitalization or death(COVERAGE trial) Traitement à domicile des personnes âgées présentant une infection symptomatique à SARS-CoV-2 (COVID-19) : un essai randomisé multi-bras multi-étapes (MAMS) pour évaluer l'efficacité et la tolérance de plusieurs traitements expérimentaux afin de diminuer le risque d'hospitalisation ou de décès

Ongoing
3
1057
Europe
Tablet, PLAQUENIL 200 mg, Imatinib Teva 400 mg, AVIGAN 200mg, MICARDIS 20mg
CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC, Ministry oh health - DGS
severe acute respiratory syndrome coronavirus 2(SARS-CoV 2) coronavirus 2 du syndrome respiratoire aigu sévère, severe acute respiratory syndrome coronavirus 2(SARS-CoV 2) coronavirus 2 du syndrome respiratoire aigu sévère, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2020-001528-32: Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals Studio randomizzato adattivo per la terapia della malattia da Corona virus 2019 a casa con antivirali orali

Ongoing
3
435
Europe
Kaletra, PLAQUENIL, REZOLSTA, Avigan, [-], Tablet, Kaletra, PLAQUENIL - 200 MG COMPRESSE RIVESTITE 30 COMPRESSE, Rezolsta, Avigan
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
Coronavirus Covid 19 infection Infezione da coronavirus Covid 19, Coronavirus Covid 19 infection Infezione da coronavirus Covid 19, Diseases [C] - Virus Diseases [C02]
 
 
NCT04558463: The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19

Recruiting
3
100
RoW
Favipiravir, Avigan® (favipiravir), Oseltamivir 75mg, Oseltamivir
Indonesia University
Covid19
09/20
10/20
NCT04411433: Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

Active, not recruiting
3
1008
RoW
Favipiravir (3200 mg + 1200 mg), Favipiravir (3600 mg + 1600 mg), Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine, Favipiravir (3200 mg + 1200 mg) combined with Azithromycin, Hydroxychloroquine, Hydroxychloroquine combined with Azithromycin
Ministry of Health, Turkey, Hacettepe University, Faculty of Medicine, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization, Umraniye Education and Research Hospital, SB Istanbul Education and Research Hospital, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey, Tepecik Training and Research Hospital, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Ankara University, Ankara City Hospital Bilkent, Ankara Training and Research Hospital, Ege University Hospital (Application and Research Center), Kocaeli Derince Education and Research Hospital, Istanbul University, Istanbul Faculty of Medicine, Kayseri City Hospital
Sars-CoV2, COVID-19
12/20
06/21
2020-005214-18: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia

Not yet recruiting
3
96
Europe
Favipiravir, T-705, Tablet
Vilnius University Hospital Santaros klinikos, Vilnius University Hospital Santaros klinikos
COVID-19 Patients without Pneumonia, COVID-19 Patients without Pneumonia, Diseases [C] - Virus Diseases [C02]
 
 
2020-005128-12: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia

Not yet recruiting
3
96
Europe
Favipiravir, T-705, Tablet
Vilnius University Hospital Santaros klinikos, Vilnius University Hospital Santaros klinikos
COVID-19 Patients with Mild Pneumonia, COVID-19 Patients with Mild Pneumonia, Diseases [C] - Virus Diseases [C02]
 
 
2020-001608-40: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients with COVID-19-Moderate Typ

Not yet recruiting
3
256
Europe
Favipiravir, Tablet
Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd.
COVID-19, viral infection with novel coronavirus SARS-COV-2, Diseases [C] - Virus Diseases [C02]
 
 
NCT04694612: Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal

Recruiting
3
676
RoW
Favipiravir, Favir 200, Placebo, Remdesivir
Nepal Health Research Council
Covid19
03/21
05/21
NCT05014373: Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19

Recruiting
3
144
RoW
Favipiravir + Standard of Care, Standard of Care
University of the Philippines, Department of Health, Philippines
Covid19
08/21
08/21
ChiCTR2000040089: A multi-center clinical study to evaluate the effectiveness and safety of favipiravir against novel Bunya virus

Not yet recruiting
3
160
 
Follow the guidelines for symptomatic support treatment ;symptomatic treatment+Favipiravir
The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Office of Research Affairs (sponsored by Zhejiang Hisun pharmaceutical)
Novel Bunya virus infection
 
 
NCT04613271: Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia

Completed
3
130
RoW
Favipiravir, Treatment Group, Azithromycin, Group 2
Ina-Respond, Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia
Infectious Disease, SARS-CoV Infection, Covid19
10/21
11/21
NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated
3
290
RoW
JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo
Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH
Moderate to Severe COVID-19
12/22
12/22
2022-001387-10: A Phase 3 blinded study to assess the efficacy and safety of Favipiravir vs placebo in Non-critical Hospitalized Patients with COVID-19 Pneumonia (PROVIR)

Ongoing
3
480
Europe
Favipiravir, Tablet, Favipiravir Tablets 200 mg - Fabiflu
TECNIMEDE, Sociedade Técnico-Medicinal, S.A., TECNIMEDE, Sociedade Técnico-Medicinal, S.A.
Coronavirus disease 2019 (COVID-19 pneumonia), Coronavirus disease 2019 (COVID-19 pneumonia), Diseases [C] - Virus Diseases [C02]
 
 
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated
3
205
Europe, RoW
Plitidepsin, Dexamethasone, Remdesivir, Favipiravir
PharmaMar
COVID-19 Infection
03/23
03/23
ChiCTR2000030987: A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19)

Recruiting
2/3
150
 
the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group ;the oral trial drug favipiravir tablets ;the oral placebo treatment
Beijing Chao-yang Hospital, Capital Medical University; Beijing Chao-yang Hospital, Major projects of the ministry of science and technology
Novel Coronavirus Pneumonia (COVID-19)
 
 
NCT04828564: Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19

Not yet recruiting
2/3
100
RoW
Ribavirin Capsules, Favipiravir
The Scientific and Technological Research Council of Turkey, Ankara City Hospital Bilkent, Istanbul Umraniye Training and Research Hospital, Koç University, Monitor CRO
SARS-CoV2, COVID-19
09/21
12/21
NCT06212336: ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Not yet recruiting
2/3
1755
NA
Favipiravir, Ribavirin, Standard of care, Dexamethasone
Irrua Specialist Teaching Hospital, Alliance for International Medical Action, University of Bordeaux, Bernhard Nocht Institute for Tropical Medicine, Federal Medical Centre, Owo, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, Fondation pour la Recherche Scientifique, Benin, Médecins Sans Frontières, Belgium, Alex Ekwueme Federal University Teaching Hospital, Donka Hospital, Conakry, Centre de Recherche Médicale de Lambaréné, University of Hamburg-Eppendorf, Phebe Hospital, Liberia, University of North Carolina, ANRS, Emerging Infectious Diseases
Lassa Fever
06/27
06/27
2020-001904-41: A study comparing favipiravir versus standard of care management as an early treatment arm in COVID-19 Hospitalized patients

Ongoing
2
302
Europe
AVIGAN, Favipiravir, Film-coated tablet, AVIGAN
NHS Greater Glasgow and Clyde, The University of Glasgow, Chief Scientists Office,
COVID-19, Coronavirus, Diseases [C] - Virus Diseases [C02]
 
 
2020-002106-68: FLARE: Favipiravir +/- Lopinavir: A RCT of Early antivirals

Ongoing
2
240
Europe
Favipiravir, Lopinavir/ritonavir, Tablet, Lopinavir/ritonavir
University College London Comprehensive Clinical Trial Unit, LifeArc
SARS-CoV-2 (Corona virus) infection, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2020-002753-22: Safety and Efficacy of Favipiravir in COVID-19 Patients with Pneumonia −A randomized, double blind, placebo- controlled study − Seguridad y eficacia de Favipiravir en pacientes COVID-19 con neumonía. − Un estudio aleatorizado, doble ciego y controlado con placebo −

Not yet recruiting
2
100
Europe
Favipiravir, Favipiravir, Tablet
Ferrer Internacional, S.A., Ferrer Internacional, S.A.
Patients diagnosed with COVID-19 by positive PCR for SARS-COV2 Pacientes diagnosticados con COVID-19 mediante PCR positiva para SARS-COV2, Coronavirus infection Infección por coronavirus, Diseases [C] - Virus Diseases [C02]
 
 
NCT04471662: Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian Patients

Not yet recruiting
2
50
NA
Nelfinavir/Favipiravir, Avigan, Active comparator, Oxygen via ventilators
Tanta University
COVID-19
11/20
12/20
NCT04448119: Control of COVID-19 Outbreaks in Long Term Care

Terminated
2
67
Canada
Favipiravir, Avigan, Favipiravir Placebo
Appili Therapeutics Inc., MOUNT SINAI HOSPITAL, Applied Health Research Centre, Sunnybrook Health Sciences Centre, University Health Network, Toronto, University of Toronto
COVID-19, SARS-CoV-2
10/21
10/21
VIRCO, NCT04445467: An Adaptive Clinical Trial of Antivirals for COVID-19 Infection

Active, not recruiting
2
190
RoW
Favipiravir
Bayside Health
COVID
11/21
12/21
NCT04718285: Investigation the Effect of Montelukast in COVID-19

Recruiting
2
380
RoW
Montelukast Oral Tablet, Montelukast plus Favicovir (Favipiravir), Favicovir (Standard Treatment)
Bahçeşehir University, Medipol University, The Scientific and Technological Research Council of Turkey
COVID-19, SARS-CoV-2
05/22
06/22
IFCOV, NCT05155527: Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients

Recruiting
2
200
RoW
Ivermectin Tablets, Placebo
Mahidol University, Prince of Songkla University
COVID-19
06/22
06/22
SAFARI, NCT04907682: Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

Completed
2
40
RoW
Ribavirin iv, Irrua regimen, Favipiravir, Avigan
Bernhard Nocht Institute for Tropical Medicine, University of Hamburg-Eppendorf, Alliance for International Medical Action, Institut National de la Santé Et de la Recherche Médicale, France, University of Bordeaux, Federal Medical Centre, Owo, Irrua Specialist Teaching Hospital
Lassa Fever
11/22
11/22
FANTAZE, NCT04918927: Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

Completed
2
120
RoW
Favipiravir, Nitazoxanide, Daxon, Nitazoxanide Placebo, Daxon Placebo
Coordinación de Investigación en Salud, Mexico, University College, London, Centro de Investigacion y Estudios Avanzados del Instituto Politecnico Nacional (CINVESTAV), Universidad Autonoma de Guadalajara, Siegfried Rhein S.A. de C.V., Strides Pharma Science Limited, Hakken Enterprise
Covid19
03/23
03/23
UMIT-1, NCT05940545: Trial Favipiravir & Ribavirin for the Treatment of CCHF

Recruiting
2
24
RoW
Favipiravir, Ribavirin
Liverpool School of Tropical Medicine
CCHF
09/23
12/23
ARSYNAL-FC, NCT06488300: Assessing Antiviral Treatments in Early Symptomatic RSV

Not yet recruiting
2
1000
RoW
Ribavirin, Molnupiravir, Favipiravir
University of Oxford
Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human
01/27
01/27
PLATCOV, NCT05041907: Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19

Recruiting
2
3800
RoW
Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Favipiravir, Ivermectin, Remdesivir, Atilotrelvir/ritonavir, Metformin, Nirmatrelvir/ritonavir, Nirmatrelvir
University of Oxford
COVID-19
01/27
01/27
AD ASTRA, NCT05648448: A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Recruiting
2
3000
RoW
Oseltamivir, Favipiravir, Zanamivir, Baloxavir, Molnupiravir, Peramivir, Laninamivir, Oseltamivir and Baloxavir, Oseltamivir and Favipiravir, Favipiravir and Baloxavir
University of Oxford
Influenza, Influenza, Human
01/27
01/27
UMIT-2, NCT06860334: - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF

Not yet recruiting
2
378
NA
Favipiravir, Ribavin, Optimised Standard of Care
Liverpool School of Tropical Medicine
Crimean-Congo Hemorrhagic Fever
12/27
08/28
NCT04715360: Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy

Recruiting
1/2
30
RoW
autologous activated platelet-rich plasma, Avigan
Hayandra Peduli Foundation, Koja Regional Public Hospital
Covid19, Sars-CoV-2 Infection, ARDS, Human, Severe covid19
11/21
12/21
NCT04746183: AGILE (Early Phase Platform Trial for COVID-19)

Hourglass Jan 2022 - Jun 2022 : Data from AGILE trial for COVID-19
Active, not recruiting
1/2
600
Europe, RoW
CST-2: EIDD-2801, MK-4482, Molnupiravir, CST-2: Placebo, Placebo, Nitazoxanide, VIR-7832, VIR-7831, Sotrovimab, CST-5: Placebo, Favipiravir, Lagevrio, Paxlovid, nirmatrelvir and ritonavir
University of Liverpool, University of Southampton, Liverpool School of Tropical Medicine, Liverpool University Hospitals NHS Foundation Trust, University of Cambridge
Covid19
07/25
07/25
NCT04651959: Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions

Active, not recruiting
1
30
RoW
AVICOD 200 MG Film Tablet, AVICOD 200mg FT, AVIGAN 200 MG Film Tablets, AVIGAN 200 mg FT
Pharma Plant, Novagenix Bioanalytical Drug R&D Center
Bioequivalence
11/20
12/20
FAVIDOSE, NCT06024421: Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

Recruiting
1
39
Europe
favipiravir, Placebo
Institut National de la Santé Et de la Recherche Médicale, France, FUJIFILM Toyama Chemical Co., Ltd.
Infectious Disease, Pharmacology
06/27
11/27
Efficacy of Favipiravir on Ebola, ChiCTR-OCN-15007272: Efficacy of Favipiravir (T-705) in patients infected with Ebola virus in Sierra Leone: a preliminary clinical trial

Completed
N/A
124
 
recommended therapy by WHO ;recommended therapy by WHO plus T705
Sierra Leone-China Friendship Hospital; The No. 307 Hospital Beijing, China, Mega-Project for Infectious Diseases of China (AWS11J011)
Ebola virus disease (EVD)
 
 
ChiCTR1900023350: Evaluation of clinical efficacy of therapy with T-705 in patients with severe fever with thrombocytopenia syndrome

Recruiting
N/A
160
 
Symptomatic treatment + T-705 treatment ;Symptomatic treatment + glucose injection
People's Liberation Army 154th Hospital; People's Liberation Army 154th Hospital, National Natural Science Foundation of China (No. 81473023，81621005)
severe fever with thrombocytopenia syndrome
 
 
ChiCTR2000030254: the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study

Completed
N/A
240
 
Farpiravir tablets ;Abidole tablets
Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University, China National Center for Biotechnology Development
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000029600: Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)

Recruiting
N/A
90
 
alpha-Interferon atomization ;Lopinavir and Ritonavir + alpha-Interferon atomization ;Favipiravir + alpha-Interferon atomization
The Third People's Hospital of Shenzhen; The Third People's Hospital of Shenzhen, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
ChiCTR2000029544: A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy

Not yet recruiting
N/A
30
China
current antiviral treatment+Baloxavir Marboxil tablets ;current antiviral treatment+fabiravir tablets ;current antiviral treatment
The First Hospital Affiliated to Zhejiang University's Medical School; The First Affiliated Hospital, Zhejiang University School of Medicine, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
ChiCTR2000030113: Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir

Recruiting
N/A
30
 
Keep ritonavir/ritonavir treatment ;Favipiravir
The Third People's Hospital of Shenzhen; None, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
ChiCTR2000029548: Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients

Not yet recruiting
N/A
30
China
BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total. ;Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days. ;Lopinavir-Ritonavir: 2# (200mg/50 mg), twice daily, for 14days.
The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
NCT04474457: Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age

Active, not recruiting
N/A
1000
RoW
Favipiravir
Ministry of Health, Turkey, Hacettepe University, School of Medicine, Prof. Dr. Cemil Tascıoglu City Hospital, Umraniye Training and Research Hospital, Istanbul Training and Research Hospital, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey, Tepecik Training and Research Hospital, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Ankara University, Ankara City Hospital Bilkent, Ankara Training and Research Hospital, Ege University Hospital (Application and Research Center), Derince Training and Research Hospital, Istanbul University, Istanbul Faculty of Medicine, Kayseri City Hospital
COVID-19
12/20
06/21
FavRem, NCT04727775: Antiviral Drugs on the Treatment of SARS-CoV-2

Completed
N/A
150
RoW
Favipiravir, Remdesivir
Astana Medical University
Complication of Medical Care, Pneumonia, Viral
07/23
07/23
ChiCTR2100043342: Clinical efficacy of therapy with T-705 in patients with severe fever with thrombocytopenia syndrome

Recruiting
N/A
1384
 
Symptomatic treatment + T-705 treatment ;Symptomatic treatment + glucose injection
The 990th Hospital of Chinese People's Liberation Army Joint Logistic Support Force; The 990th Hospital of Chinese People's Liberation Army Joint Logistic Support Force, National Natural Science Foundation of China (No. 81473023)
severe fever with thrombocytopenia syndrome
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
favipiravir / Generic mfg.
ChiCTR1800015894: Clinical efficacy of therapy with T-705 in patients with severe fever with thrombocytopenia syndrome

Recruiting
4
160
 
Symptomatic treatment + T-705 treatment ; Symptomatic treatment + glucose injection
Beijing Institute of Microbiology and Epidemiology; People 's Liberation Army154 Hospital, National Natural Science Foundation of China (No. 81473023)
severe fever with thrombocytopenia syndrome
 
 
Favipiravir for SARS-Cov-2, ChiCTR2000033491: Oral Favipiravir for Patients with Delayed SARS-Cov-2 viral RNA Clearance

Completed
4
9
 
oral Favipiravir
Wuhan Huoshenshan Hosptial; Huoshenshan Hospital, Huoshenshan Hospita
Novel Coronavirus Pneumonia (COVID-19); viral infection
 
 
ChiCTR2000030894: Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial

Recruiting
4
150
 
Favipiravir Combined With Tocilizumab ;Favipiravir ;Tocilizumab
Peking University First Hospital; Peking University First Hospital, self-financed
Novel Coronavirus Pneumonia (COVID-19)
 
 
2020-001435-27: Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safetyof several experimental treatments to reduce the risk of hospitalization or death(COVERAGE trial) Traitement à domicile des personnes âgées présentant une infection symptomatique à SARS-CoV-2 (COVID-19) : un essai randomisé multi-bras multi-étapes (MAMS) pour évaluer l'efficacité et la tolérance de plusieurs traitements expérimentaux afin de diminuer le risque d'hospitalisation ou de décès

Ongoing
3
1057
Europe
Tablet, PLAQUENIL 200 mg, Imatinib Teva 400 mg, AVIGAN 200mg, MICARDIS 20mg
CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC, Ministry oh health - DGS
severe acute respiratory syndrome coronavirus 2(SARS-CoV 2) coronavirus 2 du syndrome respiratoire aigu sévère, severe acute respiratory syndrome coronavirus 2(SARS-CoV 2) coronavirus 2 du syndrome respiratoire aigu sévère, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2020-001528-32: Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals Studio randomizzato adattivo per la terapia della malattia da Corona virus 2019 a casa con antivirali orali

Ongoing
3
435
Europe
Kaletra, PLAQUENIL, REZOLSTA, Avigan, [-], Tablet, Kaletra, PLAQUENIL - 200 MG COMPRESSE RIVESTITE 30 COMPRESSE, Rezolsta, Avigan
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
Coronavirus Covid 19 infection Infezione da coronavirus Covid 19, Coronavirus Covid 19 infection Infezione da coronavirus Covid 19, Diseases [C] - Virus Diseases [C02]
 
 
NCT04558463: The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19

Recruiting
3
100
RoW
Favipiravir, Avigan® (favipiravir), Oseltamivir 75mg, Oseltamivir
Indonesia University
Covid19
09/20
10/20
NCT04411433: Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

Active, not recruiting
3
1008
RoW
Favipiravir (3200 mg + 1200 mg), Favipiravir (3600 mg + 1600 mg), Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine, Favipiravir (3200 mg + 1200 mg) combined with Azithromycin, Hydroxychloroquine, Hydroxychloroquine combined with Azithromycin
Ministry of Health, Turkey, Hacettepe University, Faculty of Medicine, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization, Umraniye Education and Research Hospital, SB Istanbul Education and Research Hospital, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey, Tepecik Training and Research Hospital, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Ankara University, Ankara City Hospital Bilkent, Ankara Training and Research Hospital, Ege University Hospital (Application and Research Center), Kocaeli Derince Education and Research Hospital, Istanbul University, Istanbul Faculty of Medicine, Kayseri City Hospital
Sars-CoV2, COVID-19
12/20
06/21
2020-005214-18: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia

Not yet recruiting
3
96
Europe
Favipiravir, T-705, Tablet
Vilnius University Hospital Santaros klinikos, Vilnius University Hospital Santaros klinikos
COVID-19 Patients without Pneumonia, COVID-19 Patients without Pneumonia, Diseases [C] - Virus Diseases [C02]
 
 
2020-005128-12: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia

Not yet recruiting
3
96
Europe
Favipiravir, T-705, Tablet
Vilnius University Hospital Santaros klinikos, Vilnius University Hospital Santaros klinikos
COVID-19 Patients with Mild Pneumonia, COVID-19 Patients with Mild Pneumonia, Diseases [C] - Virus Diseases [C02]
 
 
2020-001608-40: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients with COVID-19-Moderate Typ

Not yet recruiting
3
256
Europe
Favipiravir, Tablet
Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd.
COVID-19, viral infection with novel coronavirus SARS-COV-2, Diseases [C] - Virus Diseases [C02]
 
 
NCT04694612: Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal

Recruiting
3
676
RoW
Favipiravir, Favir 200, Placebo, Remdesivir
Nepal Health Research Council
Covid19
03/21
05/21
NCT05014373: Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19

Recruiting
3
144
RoW
Favipiravir + Standard of Care, Standard of Care
University of the Philippines, Department of Health, Philippines
Covid19
08/21
08/21
ChiCTR2000040089: A multi-center clinical study to evaluate the effectiveness and safety of favipiravir against novel Bunya virus

Not yet recruiting
3
160
 
Follow the guidelines for symptomatic support treatment ;symptomatic treatment+Favipiravir
The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Office of Research Affairs (sponsored by Zhejiang Hisun pharmaceutical)
Novel Bunya virus infection
 
 
NCT04613271: Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia

Completed
3
130
RoW
Favipiravir, Treatment Group, Azithromycin, Group 2
Ina-Respond, Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia
Infectious Disease, SARS-CoV Infection, Covid19
10/21
11/21
NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated
3
290
RoW
JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo
Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH
Moderate to Severe COVID-19
12/22
12/22
2022-001387-10: A Phase 3 blinded study to assess the efficacy and safety of Favipiravir vs placebo in Non-critical Hospitalized Patients with COVID-19 Pneumonia (PROVIR)

Ongoing
3
480
Europe
Favipiravir, Tablet, Favipiravir Tablets 200 mg - Fabiflu
TECNIMEDE, Sociedade Técnico-Medicinal, S.A., TECNIMEDE, Sociedade Técnico-Medicinal, S.A.
Coronavirus disease 2019 (COVID-19 pneumonia), Coronavirus disease 2019 (COVID-19 pneumonia), Diseases [C] - Virus Diseases [C02]
 
 
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated
3
205
Europe, RoW
Plitidepsin, Dexamethasone, Remdesivir, Favipiravir
PharmaMar
COVID-19 Infection
03/23
03/23
ChiCTR2000030987: A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19)

Recruiting
2/3
150
 
the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group ;the oral trial drug favipiravir tablets ;the oral placebo treatment
Beijing Chao-yang Hospital, Capital Medical University; Beijing Chao-yang Hospital, Major projects of the ministry of science and technology
Novel Coronavirus Pneumonia (COVID-19)
 
 
NCT04828564: Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19

Not yet recruiting
2/3
100
RoW
Ribavirin Capsules, Favipiravir
The Scientific and Technological Research Council of Turkey, Ankara City Hospital Bilkent, Istanbul Umraniye Training and Research Hospital, Koç University, Monitor CRO
SARS-CoV2, COVID-19
09/21
12/21
NCT06212336: ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Not yet recruiting
2/3
1755
NA
Favipiravir, Ribavirin, Standard of care, Dexamethasone
Irrua Specialist Teaching Hospital, Alliance for International Medical Action, University of Bordeaux, Bernhard Nocht Institute for Tropical Medicine, Federal Medical Centre, Owo, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, Fondation pour la Recherche Scientifique, Benin, Médecins Sans Frontières, Belgium, Alex Ekwueme Federal University Teaching Hospital, Donka Hospital, Conakry, Centre de Recherche Médicale de Lambaréné, University of Hamburg-Eppendorf, Phebe Hospital, Liberia, University of North Carolina, ANRS, Emerging Infectious Diseases
Lassa Fever
06/27
06/27
2020-001904-41: A study comparing favipiravir versus standard of care management as an early treatment arm in COVID-19 Hospitalized patients

Ongoing
2
302
Europe
AVIGAN, Favipiravir, Film-coated tablet, AVIGAN
NHS Greater Glasgow and Clyde, The University of Glasgow, Chief Scientists Office,
COVID-19, Coronavirus, Diseases [C] - Virus Diseases [C02]
 
 
2020-002106-68: FLARE: Favipiravir +/- Lopinavir: A RCT of Early antivirals

Ongoing
2
240
Europe
Favipiravir, Lopinavir/ritonavir, Tablet, Lopinavir/ritonavir
University College London Comprehensive Clinical Trial Unit, LifeArc
SARS-CoV-2 (Corona virus) infection, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2020-002753-22: Safety and Efficacy of Favipiravir in COVID-19 Patients with Pneumonia −A randomized, double blind, placebo- controlled study − Seguridad y eficacia de Favipiravir en pacientes COVID-19 con neumonía. − Un estudio aleatorizado, doble ciego y controlado con placebo −

Not yet recruiting
2
100
Europe
Favipiravir, Favipiravir, Tablet
Ferrer Internacional, S.A., Ferrer Internacional, S.A.
Patients diagnosed with COVID-19 by positive PCR for SARS-COV2 Pacientes diagnosticados con COVID-19 mediante PCR positiva para SARS-COV2, Coronavirus infection Infección por coronavirus, Diseases [C] - Virus Diseases [C02]
 
 
NCT04471662: Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian Patients

Not yet recruiting
2
50
NA
Nelfinavir/Favipiravir, Avigan, Active comparator, Oxygen via ventilators
Tanta University
COVID-19
11/20
12/20
NCT04448119: Control of COVID-19 Outbreaks in Long Term Care

Terminated
2
67
Canada
Favipiravir, Avigan, Favipiravir Placebo
Appili Therapeutics Inc., MOUNT SINAI HOSPITAL, Applied Health Research Centre, Sunnybrook Health Sciences Centre, University Health Network, Toronto, University of Toronto
COVID-19, SARS-CoV-2
10/21
10/21
VIRCO, NCT04445467: An Adaptive Clinical Trial of Antivirals for COVID-19 Infection

Active, not recruiting
2
190
RoW
Favipiravir
Bayside Health
COVID
11/21
12/21
NCT04718285: Investigation the Effect of Montelukast in COVID-19

Recruiting
2
380
RoW
Montelukast Oral Tablet, Montelukast plus Favicovir (Favipiravir), Favicovir (Standard Treatment)
Bahçeşehir University, Medipol University, The Scientific and Technological Research Council of Turkey
COVID-19, SARS-CoV-2
05/22
06/22
IFCOV, NCT05155527: Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients

Recruiting
2
200
RoW
Ivermectin Tablets, Placebo
Mahidol University, Prince of Songkla University
COVID-19
06/22
06/22
SAFARI, NCT04907682: Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

Completed
2
40
RoW
Ribavirin iv, Irrua regimen, Favipiravir, Avigan
Bernhard Nocht Institute for Tropical Medicine, University of Hamburg-Eppendorf, Alliance for International Medical Action, Institut National de la Santé Et de la Recherche Médicale, France, University of Bordeaux, Federal Medical Centre, Owo, Irrua Specialist Teaching Hospital
Lassa Fever
11/22
11/22
FANTAZE, NCT04918927: Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

Completed
2
120
RoW
Favipiravir, Nitazoxanide, Daxon, Nitazoxanide Placebo, Daxon Placebo
Coordinación de Investigación en Salud, Mexico, University College, London, Centro de Investigacion y Estudios Avanzados del Instituto Politecnico Nacional (CINVESTAV), Universidad Autonoma de Guadalajara, Siegfried Rhein S.A. de C.V., Strides Pharma Science Limited, Hakken Enterprise
Covid19
03/23
03/23
UMIT-1, NCT05940545: Trial Favipiravir & Ribavirin for the Treatment of CCHF

Recruiting
2
24
RoW
Favipiravir, Ribavirin
Liverpool School of Tropical Medicine
CCHF
09/23
12/23
ARSYNAL-FC, NCT06488300: Assessing Antiviral Treatments in Early Symptomatic RSV

Not yet recruiting
2
1000
RoW
Ribavirin, Molnupiravir, Favipiravir
University of Oxford
Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human
01/27
01/27
PLATCOV, NCT05041907: Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19

Recruiting
2
3800
RoW
Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Favipiravir, Ivermectin, Remdesivir, Atilotrelvir/ritonavir, Metformin, Nirmatrelvir/ritonavir, Nirmatrelvir
University of Oxford
COVID-19
01/27
01/27
AD ASTRA, NCT05648448: A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Recruiting
2
3000
RoW
Oseltamivir, Favipiravir, Zanamivir, Baloxavir, Molnupiravir, Peramivir, Laninamivir, Oseltamivir and Baloxavir, Oseltamivir and Favipiravir, Favipiravir and Baloxavir
University of Oxford
Influenza, Influenza, Human
01/27
01/27
UMIT-2, NCT06860334: - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF

Not yet recruiting
2
378
NA
Favipiravir, Ribavin, Optimised Standard of Care
Liverpool School of Tropical Medicine
Crimean-Congo Hemorrhagic Fever
12/27
08/28
NCT04715360: Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy

Recruiting
1/2
30
RoW
autologous activated platelet-rich plasma, Avigan
Hayandra Peduli Foundation, Koja Regional Public Hospital
Covid19, Sars-CoV-2 Infection, ARDS, Human, Severe covid19
11/21
12/21
NCT04746183: AGILE (Early Phase Platform Trial for COVID-19)

Hourglass Jan 2022 - Jun 2022 : Data from AGILE trial for COVID-19
Active, not recruiting
1/2
600
Europe, RoW
CST-2: EIDD-2801, MK-4482, Molnupiravir, CST-2: Placebo, Placebo, Nitazoxanide, VIR-7832, VIR-7831, Sotrovimab, CST-5: Placebo, Favipiravir, Lagevrio, Paxlovid, nirmatrelvir and ritonavir
University of Liverpool, University of Southampton, Liverpool School of Tropical Medicine, Liverpool University Hospitals NHS Foundation Trust, University of Cambridge
Covid19
07/25
07/25
NCT04651959: Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions

Active, not recruiting
1
30
RoW
AVICOD 200 MG Film Tablet, AVICOD 200mg FT, AVIGAN 200 MG Film Tablets, AVIGAN 200 mg FT
Pharma Plant, Novagenix Bioanalytical Drug R&D Center
Bioequivalence
11/20
12/20
FAVIDOSE, NCT06024421: Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

Recruiting
1
39
Europe
favipiravir, Placebo
Institut National de la Santé Et de la Recherche Médicale, France, FUJIFILM Toyama Chemical Co., Ltd.
Infectious Disease, Pharmacology
06/27
11/27
Efficacy of Favipiravir on Ebola, ChiCTR-OCN-15007272: Efficacy of Favipiravir (T-705) in patients infected with Ebola virus in Sierra Leone: a preliminary clinical trial

Completed
N/A
124
 
recommended therapy by WHO ;recommended therapy by WHO plus T705
Sierra Leone-China Friendship Hospital; The No. 307 Hospital Beijing, China, Mega-Project for Infectious Diseases of China (AWS11J011)
Ebola virus disease (EVD)
 
 
ChiCTR1900023350: Evaluation of clinical efficacy of therapy with T-705 in patients with severe fever with thrombocytopenia syndrome

Recruiting
N/A
160
 
Symptomatic treatment + T-705 treatment ;Symptomatic treatment + glucose injection
People's Liberation Army 154th Hospital; People's Liberation Army 154th Hospital, National Natural Science Foundation of China (No. 81473023，81621005)
severe fever with thrombocytopenia syndrome
 
 
ChiCTR2000030254: the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study

Completed
N/A
240
 
Farpiravir tablets ;Abidole tablets
Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University, China National Center for Biotechnology Development
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000029600: Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)

Recruiting
N/A
90
 
alpha-Interferon atomization ;Lopinavir and Ritonavir + alpha-Interferon atomization ;Favipiravir + alpha-Interferon atomization
The Third People's Hospital of Shenzhen; The Third People's Hospital of Shenzhen, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
ChiCTR2000029544: A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy

Not yet recruiting
N/A
30
China
current antiviral treatment+Baloxavir Marboxil tablets ;current antiviral treatment+fabiravir tablets ;current antiviral treatment
The First Hospital Affiliated to Zhejiang University's Medical School; The First Affiliated Hospital, Zhejiang University School of Medicine, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
ChiCTR2000030113: Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir

Recruiting
N/A
30
 
Keep ritonavir/ritonavir treatment ;Favipiravir
The Third People's Hospital of Shenzhen; None, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
ChiCTR2000029548: Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients

Not yet recruiting
N/A
30
China
BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total. ;Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days. ;Lopinavir-Ritonavir: 2# (200mg/50 mg), twice daily, for 14days.
The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
NCT04474457: Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age

Active, not recruiting
N/A
1000
RoW
Favipiravir
Ministry of Health, Turkey, Hacettepe University, School of Medicine, Prof. Dr. Cemil Tascıoglu City Hospital, Umraniye Training and Research Hospital, Istanbul Training and Research Hospital, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey, Tepecik Training and Research Hospital, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Ankara University, Ankara City Hospital Bilkent, Ankara Training and Research Hospital, Ege University Hospital (Application and Research Center), Derince Training and Research Hospital, Istanbul University, Istanbul Faculty of Medicine, Kayseri City Hospital
COVID-19
12/20
06/21
FavRem, NCT04727775: Antiviral Drugs on the Treatment of SARS-CoV-2

Completed
N/A
150
RoW
Favipiravir, Remdesivir
Astana Medical University
Complication of Medical Care, Pneumonia, Viral
07/23
07/23
ChiCTR2100043342: Clinical efficacy of therapy with T-705 in patients with severe fever with thrombocytopenia syndrome

Recruiting
N/A
1384
 
Symptomatic treatment + T-705 treatment ;Symptomatic treatment + glucose injection
The 990th Hospital of Chinese People's Liberation Army Joint Logistic Support Force; The 990th Hospital of Chinese People's Liberation Army Joint Logistic Support Force, National Natural Science Foundation of China (No. 81473023)
severe fever with thrombocytopenia syndrome
 
 

Download Options